Ocular Therapeutix Competitors

Biohaven Pharmaceutical (NYSE:BHVN) and Ocular Therapeutix (NASDAQ:OCUL) are both medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their risk, analyst recommendations, profitability, valuation, dividends, institutional ownership and earnings.

Insider & Institutional Ownership

99.4% of Biohaven Pharmaceutical shares are held by institutional investors. Comparatively, 52.5% of Ocular Therapeutix shares are held by institutional investors. 19.1% of Biohaven Pharmaceutical shares are held by company insiders. Comparatively, 7.7% of Ocular Therapeutix shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Analyst Ratings

This is a summary of current recommendations for Biohaven Pharmaceutical and Ocular Therapeutix, as reported by MarketBeat.com.

Biohaven Pharmaceutical currently has a consensus target price of $96.4545, suggesting a potential upside of 28.95%. Ocular Therapeutix has a consensus target price of $24.80, suggesting a potential upside of 50.30%. Given Ocular Therapeutix's stronger consensus rating and higher possible upside, analysts clearly believe Ocular Therapeutix is more favorable than Biohaven Pharmaceutical.

Risk and Volatility

Biohaven Pharmaceutical has a beta of 1.09, suggesting that its stock price is 9% more volatile than the S&P 500. Comparatively, Ocular Therapeutix has a beta of 2.29, suggesting that its stock price is 129% more volatile than the S&P 500.

Profitability

This table compares Biohaven Pharmaceutical and Ocular Therapeutix's net margins, return on equity and return on assets.

Valuation & Earnings

This table compares Biohaven Pharmaceutical and Ocular Therapeutix's gross revenue, earnings per share and valuation.

Ocular Therapeutix has higher revenue and earnings than Biohaven Pharmaceutical. Ocular Therapeutix is trading at a lower price-to-earnings ratio than Biohaven Pharmaceutical, indicating that it is currently the more affordable of the two stocks.

Summary

Ocular Therapeutix beats Biohaven Pharmaceutical on 8 of the 14 factors compared between the two stocks.

Ocular Therapeutix (NASDAQ:OCUL) and Atea Pharmaceuticals (NASDAQ:AVIR) are both medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, valuation, earnings, dividends, risk, analyst recommendations and institutional ownership.

Institutional & Insider Ownership

52.5% of Ocular Therapeutix shares are held by institutional investors. 7.7% of Ocular Therapeutix shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Analyst Recommendations

This is a breakdown of recent recommendations and price targets for Ocular Therapeutix and Atea Pharmaceuticals, as provided by MarketBeat.

Ocular Therapeutix presently has a consensus target price of $24.80, suggesting a potential upside of 50.30%. Atea Pharmaceuticals has a consensus target price of $69.3333, suggesting a potential upside of 27.03%. Given Ocular Therapeutix's higher possible upside, equities analysts clearly believe Ocular Therapeutix is more favorable than Atea Pharmaceuticals.

Profitability

This table compares Ocular Therapeutix and Atea Pharmaceuticals' net margins, return on equity and return on assets.

Earnings & Valuation

This table compares Ocular Therapeutix and Atea Pharmaceuticals' revenue, earnings per share (EPS) and valuation.

Atea Pharmaceuticals has lower revenue, but higher earnings than Ocular Therapeutix.

Summary

Ocular Therapeutix beats Atea Pharmaceuticals on 5 of the 9 factors compared between the two stocks.

Ocular Therapeutix (NASDAQ:OCUL) and Sage Therapeutics (NASDAQ:SAGE) are both medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, valuation, earnings, dividends, risk, analyst recommendations and institutional ownership.

Institutional & Insider Ownership

52.5% of Ocular Therapeutix shares are held by institutional investors. 7.7% of Ocular Therapeutix shares are held by insiders. Comparatively, 4.8% of Sage Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Analyst Recommendations

This is a breakdown of recent recommendations and price targets for Ocular Therapeutix and Sage Therapeutics, as provided by MarketBeat.

Ocular Therapeutix presently has a consensus target price of $24.80, suggesting a potential upside of 50.30%. Sage Therapeutics has a consensus target price of $87.0625, suggesting a potential upside of 15.06%. Given Ocular Therapeutix's stronger consensus rating and higher possible upside, equities analysts clearly believe Ocular Therapeutix is more favorable than Sage Therapeutics.

Risk & Volatility

Ocular Therapeutix has a beta of 2.29, meaning that its stock price is 129% more volatile than the S&P 500. Comparatively, Sage Therapeutics has a beta of 2.23, meaning that its stock price is 123% more volatile than the S&P 500.

Profitability

This table compares Ocular Therapeutix and Sage Therapeutics' net margins, return on equity and return on assets.

Earnings & Valuation

This table compares Ocular Therapeutix and Sage Therapeutics' revenue, earnings per share (EPS) and valuation.

Ocular Therapeutix has higher earnings, but lower revenue than Sage Therapeutics. Ocular Therapeutix is trading at a lower price-to-earnings ratio than Sage Therapeutics, indicating that it is currently the more affordable of the two stocks.

Summary

Ocular Therapeutix beats Sage Therapeutics on 9 of the 15 factors compared between the two stocks.

Ocular Therapeutix (NASDAQ:OCUL) and Hutchison China MediTech (NASDAQ:HCM) are both medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, valuation, earnings, dividends, risk, analyst recommendations and institutional ownership.

Institutional & Insider Ownership

52.5% of Ocular Therapeutix shares are held by institutional investors. Comparatively, 33.5% of Hutchison China MediTech shares are held by institutional investors. 7.7% of Ocular Therapeutix shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Analyst Recommendations

This is a breakdown of recent recommendations and price targets for Ocular Therapeutix and Hutchison China MediTech, as provided by MarketBeat.

Ocular Therapeutix presently has a consensus target price of $24.80, suggesting a potential upside of 50.30%. Hutchison China MediTech has a consensus target price of $40.00, suggesting a potential upside of 37.03%. Given Ocular Therapeutix's higher possible upside, equities analysts clearly believe Ocular Therapeutix is more favorable than Hutchison China MediTech.

Risk & Volatility

Ocular Therapeutix has a beta of 2.29, meaning that its stock price is 129% more volatile than the S&P 500. Comparatively, Hutchison China MediTech has a beta of 1.12, meaning that its stock price is 12% more volatile than the S&P 500.

Profitability

This table compares Ocular Therapeutix and Hutchison China MediTech's net margins, return on equity and return on assets.

Earnings & Valuation

This table compares Ocular Therapeutix and Hutchison China MediTech's revenue, earnings per share (EPS) and valuation.

Ocular Therapeutix has higher earnings, but lower revenue than Hutchison China MediTech. Hutchison China MediTech is trading at a lower price-to-earnings ratio than Ocular Therapeutix, indicating that it is currently the more affordable of the two stocks.

Summary

Ocular Therapeutix beats Hutchison China MediTech on 8 of the 13 factors compared between the two stocks.

Ocular Therapeutix (NASDAQ:OCUL) and Arena Pharmaceuticals (NASDAQ:ARNA) are both medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, valuation, earnings, dividends, risk, analyst recommendations and institutional ownership.

Institutional & Insider Ownership

52.5% of Ocular Therapeutix shares are held by institutional investors. Comparatively, 89.7% of Arena Pharmaceuticals shares are held by institutional investors. 7.7% of Ocular Therapeutix shares are held by insiders. Comparatively, 3.1% of Arena Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Analyst Recommendations

This is a breakdown of recent recommendations and price targets for Ocular Therapeutix and Arena Pharmaceuticals, as provided by MarketBeat.

Ocular Therapeutix presently has a consensus target price of $24.80, suggesting a potential upside of 50.30%. Arena Pharmaceuticals has a consensus target price of $92.80, suggesting a potential upside of 37.20%. Given Ocular Therapeutix's higher possible upside, equities analysts clearly believe Ocular Therapeutix is more favorable than Arena Pharmaceuticals.

Risk & Volatility

Ocular Therapeutix has a beta of 2.29, meaning that its stock price is 129% more volatile than the S&P 500. Comparatively, Arena Pharmaceuticals has a beta of 0.83, meaning that its stock price is 17% less volatile than the S&P 500.

Profitability

This table compares Ocular Therapeutix and Arena Pharmaceuticals' net margins, return on equity and return on assets.

Earnings & Valuation

This table compares Ocular Therapeutix and Arena Pharmaceuticals' revenue, earnings per share (EPS) and valuation.

Arena Pharmaceuticals has higher revenue and earnings than Ocular Therapeutix. Ocular Therapeutix is trading at a lower price-to-earnings ratio than Arena Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Summary

Arena Pharmaceuticals beats Ocular Therapeutix on 8 of the 14 factors compared between the two stocks.

Ocular Therapeutix (NASDAQ:OCUL) and Emergent BioSolutions (NYSE:EBS) are both medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, valuation, earnings, dividends, risk, analyst recommendations and institutional ownership.

Profitability

This table compares Ocular Therapeutix and Emergent BioSolutions' net margins, return on equity and return on assets.

Earnings & Valuation

This table compares Ocular Therapeutix and Emergent BioSolutions' revenue, earnings per share (EPS) and valuation.

Emergent BioSolutions has higher revenue and earnings than Ocular Therapeutix. Ocular Therapeutix is trading at a lower price-to-earnings ratio than Emergent BioSolutions, indicating that it is currently the more affordable of the two stocks.

Risk & Volatility

Ocular Therapeutix has a beta of 2.29, meaning that its stock price is 129% more volatile than the S&P 500. Comparatively, Emergent BioSolutions has a beta of 1.26, meaning that its stock price is 26% more volatile than the S&P 500.

Institutional & Insider Ownership

52.5% of Ocular Therapeutix shares are held by institutional investors. Comparatively, 80.2% of Emergent BioSolutions shares are held by institutional investors. 7.7% of Ocular Therapeutix shares are held by insiders. Comparatively, 14.1% of Emergent BioSolutions shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Analyst Recommendations

This is a breakdown of recent recommendations and price targets for Ocular Therapeutix and Emergent BioSolutions, as provided by MarketBeat.

Ocular Therapeutix presently has a consensus target price of $24.80, suggesting a potential upside of 50.30%. Emergent BioSolutions has a consensus target price of $113.6667, suggesting a potential upside of 52.63%. Given Emergent BioSolutions' higher possible upside, analysts clearly believe Emergent BioSolutions is more favorable than Ocular Therapeutix.

Summary

Emergent BioSolutions beats Ocular Therapeutix on 11 of the 15 factors compared between the two stocks.